From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP — BiobankSNI

Nephrotic Syndrome Clinical Trial

Official title:
From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With Minimal Glomerular Injury Nephrotic Syndrome (MGLS) and Primary Segmental and Focal Hyalinosis (HSFP)

Status Recruiting

Clinical Trial Summary

Idiopathic Nephrotic Syndrome (INS) is a kidney disease characterized by massive proteinuria and hypoalbuminemia. It includes two anatomopathological entities: nephrotic syndrome with minimal glomerular lesions (SNLGM) and primary segmental and focal hyalinosis (PHF). Renal biopsy reveals a fusion of the feet of the podocytes without inflammatory lesions or deposits of immune complexes. Clinical and experimental observations strongly suggest that the immune system and podocyte dysfunction are the two facets of the disease. There are currently no clinical or biological markers to predict the diagnosis of corticosteroid sensitivity, corticosteroid dependence, or risk of recurrence of kidney disease after kidney transplantation. To our knowledge, no prospective studies have been designed to study both immune system alterations and podocyte damage as well as genetic predisposition variants in NIS. Therefore, the use of steroids/immunosuppressive agents is purely empirical with a multitude of side effects. The objective is to identify and test new therapeutic targets rather than conducting new trials with existing treatments, using either drug candidates or molecules selected by high throughput screening of libraries of repositioning molecules using an appropriate read-out. The biobank may also be used to analyze the effects of conventional treatments on identified new biomarkers. We expect the project to produce original and patentable results with subsequent valuation. Patentability will be anticipated before any publication on the subject. The patent and valorization cells of hospitals, INSERM and Universities will be involved in the results as soon as they are obtained.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04174066
Study type	Observational
Source	Centre Hospitalier Universitaire de Nice
Contact	Barbara SEITZ POLSKI
Phone	33 4 92 03 55 02
Email	seitz-polski.b@chu-nice.fr
Status	Recruiting
Phase
Start date	May 20, 2020
Completion date	May 20, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02238418` - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.	Phase 4
Completed	`NCT01895894` - Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome	Phase 4
Completed	`NCT01411982` - Role of PACAP in Nehprotic Syndrome	N/A
Recruiting	`NCT00308321` - Long Term Tapering or Standard Steroids for Nephrotic Syndrome	Phase 4
Active, not recruiting	`NCT03326037` - Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Completed	`NCT01252901` - Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases	N/A
Completed	`NCT01197040` - Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome	Phase 3
Terminated	`NCT00883636` - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis	N/A
Completed	`NCT00035334` - Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis	Phase 2/Phase 3
Terminated	`NCT00004466` - Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome	Phase 2
Terminated	`NCT04558892` - Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.	Phase 2/Phase 3
Completed	`NCT02257697` - A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome	Phase 3
Completed	`NCT00362531` - Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome	Phase 2/Phase 3
Completed	`NCT00289328` - Glucocorticoid-induced Osteopenia in Children	N/A
Recruiting	`NCT04759274` - Diuretic Tuner Clinical Decision Support	N/A
Completed	`NCT00001212` - Drug Therapy in Lupus Nephropathy	Phase 2
Recruiting	`NCT05623033` - The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
Completed	`NCT03332420` - The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
Not yet recruiting	`NCT05904197` - Effectiveness of Educational Gamified Cards About Nephrotic Syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.